77 related articles for article (PubMed ID: 25053682)
1. Use of BRAF V600E as a molecular marker in aggressive colorectal cancer.
Hernowo BS; Ariyanni F; Suryanti S; Hassan AH
Acta Med Indones; 2014 Apr; 46(2):104-10. PubMed ID: 25053682
[TBL] [Abstract][Full Text] [Related]
2. Co-existence of BRAF V600E Gene Mutation in Tumor and Non-tumoral Surrounding Tissues in Colorectal Cancer.
Öztürk T; Toptaş-Hekimoğlu B; Eronat AP; Saygili N; Dağlar-Aday A; Başsüllü N; Türkmen I; Aydoğan HY; Bülbül G; Göksel S; Öztürk O; Isbir T
In Vivo; 2015; 29(5):577-84. PubMed ID: 26359417
[TBL] [Abstract][Full Text] [Related]
3. [BRAF mutation in colorectal serrated lesions].
Zhou ZY; Han Y; Wang LP
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3411-4. PubMed ID: 19159571
[TBL] [Abstract][Full Text] [Related]
4. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
[TBL] [Abstract][Full Text] [Related]
5. Stereologic estimates of volume-weighted mean nuclear volume in colorectal adenocarcinoma: correlation with histologic grading, Dukes' staging, cell proliferation activity and p53 protein expression.
Martín R; Nieto S; Santamaría L
Gen Diagn Pathol; 1997 Jul; 143(1):29-38. PubMed ID: 9269906
[TBL] [Abstract][Full Text] [Related]
6. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
Kuan SF; Navina S; Cressman KL; Pai RK
Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
[TBL] [Abstract][Full Text] [Related]
8. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
9. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.
Caplin S; Cerottini JP; Bosman FT; Constanda MT; Givel JC
Cancer; 1998 Aug; 83(4):666-72. PubMed ID: 9708929
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.
Vakiani E; Yaeger R; Brooke S; Zhou Y; Klimstra DS; Shia J
Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):438-43. PubMed ID: 25517872
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E Mutations in Endometrial Adenocarcinoma.
He M; Breese V; Hang S; Zhang C; Xiong J; Jackson C
Diagn Mol Pathol; 2013 Mar; 22(1):35-40. PubMed ID: 23370429
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity.
Bledsoe JR; Kamionek M; Mino-Kenudson M
Am J Surg Pathol; 2014 Oct; 38(10):1418-28. PubMed ID: 24921639
[TBL] [Abstract][Full Text] [Related]
13. Morphological evaluation of colorectal carcinoma with grading staging and histological types.
Nabi U; Nagi AH; Riaz S; Sami W
J Pak Med Assoc; 2010 Dec; 60(12):998-1001. PubMed ID: 21381550
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
[TBL] [Abstract][Full Text] [Related]
15. The impact of surgeon and pathologist on lymph node retrieval in colorectal cancer and its impact on survival for patients with Dukes' stage B disease.
Evans MD; Barton K; Rees A; Stamatakis JD; Karandikar SS
Colorectal Dis; 2008 Feb; 10(2):157-64. PubMed ID: 17477849
[TBL] [Abstract][Full Text] [Related]
16. How many lymph nodes should be examined in Dukes' B colorectal cancer? Determination on the basis of cumulative survival rate.
Yoshimatsu K; Ishibashi K; Umehara A; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
Hepatogastroenterology; 2005; 52(66):1703-6. PubMed ID: 16334761
[TBL] [Abstract][Full Text] [Related]
17. Different distribution of Dukes' stage between proximal and distal colorectal cancer.
Ikeda Y; Akagi K; Kinoshita J; Abe T; Miyazaki M; Mori M; Sugimachi K
Hepatogastroenterology; 2002; 49(48):1535-7. PubMed ID: 12397728
[TBL] [Abstract][Full Text] [Related]
18. A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma.
Kim YH; Choi SE; Yoon SO; Hong SW
Hum Pathol; 2014 Jul; 45(7):1483-8. PubMed ID: 24745617
[TBL] [Abstract][Full Text] [Related]
19. Analysis of DNA mismatch repair proteins expression and BRAF V600E mutation in a subset of early- and late-onset colorectal carcinoma patients in Mexico.
Luévano-González A; Guzmán AQ; Ancer Rodríguez J; Ortiz López R; Rojas Martínez A; González Guerrero JF; Flores Gutiérrez JP
Arch Med Res; 2011 Aug; 42(6):457-62. PubMed ID: 21945875
[TBL] [Abstract][Full Text] [Related]
20. Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for Hereditary Nonpolyposis Colorectal Cancer.
Kadiyska TK; Konstantinova DV; Atanasov VR; Kremensky IM; Mitev VI
Cancer Detect Prev; 2007; 31(3):254-6. PubMed ID: 17566669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
